$599

Novartis Post-ACC CV Investor Event Highlights; Inclisiran Expected as Class 2 Review

Today, Novartis hosted a post-ACC cardiovascular investor event in which it provided updates across its business, including Entresto, Leqvio (inclisiran), and pelacarsen (Lp(a)). Below, FENIX provides highlights and insights from the event including thoughts on inclisiran receiving a Class 2 review.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.